Search Results 1731-1740 of 11196 for total t4

  1. A Study Comparing Temozolomide and Selumetinib for Treating Patients with Metastatic Melanoma of the Eye - Mayo Clinic

    Total bilirubin ≤ 1.5 times upper limit of normal. Hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g. ...

  2. A Study to Assess the Effectiveness and Safety of Ublituximab in combination with Umbralisib and Venetoclax (U2-V) Compared to Ublituximab and Umbralisib (U2) in Subjects with Chronic Lymphocytic Leukemia (CLL) - Mayo Clinic

    Total bilirubin ≤ 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome with bilirubin > 1.5 × ULN allowed per discussion with the ...

  3. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

    Total bilirubin ≤ 1.5 x upper limit of normal (ULN), unless due to Gilbert's disease;; Aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ...

  4. Bladder Removal Surgery Clinical Trials - Mayo Clinic Research

    The dual primary hypotheses are preoperative EV + pembrolizumab and RC + PLND (Arm A) will achieve superior pathologic complete response (pCR) rate and ...

  5. Phase I/II Study Of The Combination Of Blinatumomab And Asciminib In Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia - Mayo Clinic

    Total serum bilirubin ≤ 2 x upper limit of normal (ULN), unless due to Gilbert's syndrome 2. Alanine aminotransferase (ALT) ≤ 3 x ULN, OR 3. Aspartate ...

  6. A Study Of ABBV-383 With Relapsed Refractory Waldenström Macroglobulinemia - Mayo Clinic

    Total bilirubin ≤1.5 x ULN (except for subjects with documented Gilbert's syndrome, in which case direct bilirubin must be ≤ 2 x ULN). Alanine ...

  7. Clinical Trials - AUTO1 in Relapsed or Refractory B-ALL

    Total bilirubin ≤ 1.5 x ULN, except in patients with Gilbert's syndrome who ... Active significant (overall Grade ≥ II, Seattle criteria) acute graft ...

  8. Neurology - Clinical trials - Mayo Clinic

    ... total toxicity profile. The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in ...

  9. Neurology - Clinical trials

    ... total toxicity profile. The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in ...

  10. Neurology - Clinical trials

    ... total toxicity profile. The purpose of phase 2 of this trial is to evaluate the effectiveness of sequentially administering temozolomide and selinexor in ...